Andarix Pharmaceuticals

Andarix Pharmaceuticals is developing and commercializing novel cancer therapies targeting patients most likely to respond. Their clinical-stage products target specific cancers at the molecular level, and their companion diagnostics identify patients with corresponding molecular profiles who are the best candidates for treatment. Their products are based on proprietary peptide-targeted radiopharmaceutical technology, which can image and subsequently kill cancer cells through targeted radiation therapy.